News GSK plc

Equities

GSK

GB00BN7SWP63

Real-time Estimate Cboe Europe Other stock markets 04:11:32 2024-04-25 am EDT			5-day change	1st Jan Change
1,642 ^GBX	+0.34%		+3.58%	+13.10%

Apr. 24	CureVac Begins Early Stage Portion of Investigational Vaccine Trial	MT
Apr. 24	Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24	MT
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	Apr. 24
GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review	Apr. 24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	Apr. 24	MT
GSK : Gets a Sell rating from JP Morgan	Apr. 24	ZD
GSK : Gets a Buy rating from Bernstein	Apr. 24	ZD
US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer \| GSK	Apr. 24	AQ
GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli	Apr. 24	CI
GSK: FDA priority review for endometrial cancer	Apr. 24	CF
GSK's Jemperli with chemotherapy accepted for priority review by FDA	Apr. 24	AN
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	Apr. 24	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	Apr. 24	RE
Edwards Lifesciences Corporation: The story continues	Apr. 23
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
GSK : Director/Pdmr Shareholding - Form 6-K	Apr. 19	PU
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	Apr. 17	AQ
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	Apr. 17	AQ
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	Apr. 17	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST